Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Abstract The Committee of Clinical Practice Guidelines of the Korean Diabetes Association
(KDA) updated the previous clinical practice guidelines for Korean adults with diabetes and …

Importance The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide
and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment …

Importance Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy and safety of …

Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …

Dysregulation of peptide-activated pathways causes a range of diseases, fostering the
discovery and clinical development of peptide drugs. Many endogenous peptides activate G …

GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …

Methods The overarching goals and methodologic principles for the Diabetes Canada CPG
are unchanged from 2018 (2, 3). Leveraging the search methods and PICO questions used …

Summary Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are an important class
of drugs with a well‐established efficacy and safety profile in patients with type 2 diabetes …

OBJECTIVE To investigate the efficacy, safety, and tolerability of oral semaglutide added to
insulin with or without metformin. RESEARCH DESIGN AND METHODS Patients with type 2 …